India CRO Market

ID: MRFR/Pharma/2151-HCR
70 Pages
Satyendra Maurya
Last Updated: June 12, 2026
์ธ๋„ CRO ์‹œ์žฅ ์กฐ์‚ฌ ๋ณด๊ณ ์„œ - 2032๋…„๊นŒ์ง€ ์ „๋ง
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

India CRO Market

Market Size

Forecast Period2025 - 2035
CAGR (2025 - 2035)6.0%
2024 Market Size$ 6.32 Billion
2025 Market Size$ 6.74 Billion
2035 Market Size$ 12 Billion

Key Players

Companies such as IQVIA
Syneos Health
PAREXEL International
Covance
Charles River Laboratories
Medpace
Opportunities
  • Growing Pharmaceutical Sector
  • Increased Focus on Clinical Trials
  • Rising Demand for Outsourcing Services
  1. 1 ์„œ๋ก 
    1. 1.1 ์ •์˜
    2. 1.2 ์—ฐ๊ตฌ ๋ฒ”์œ„
    3. 1.3 ์—ฐ๊ตฌ ๋ชฉํ‘œ
    4. 1.4 ๊ฐ€์ • ๋ฐ ์ œํ•œ ์‚ฌํ•ญ
    5. 1.5 ์‹œ์žฅ ๊ตฌ์กฐ:
  2. 2 ์—ฐ๊ตฌ ๋ฐฉ๋ฒ•๋ก 
    1. 2.1 ์—ฐ๊ตฌ ํ”„๋กœ์„ธ์Šค
    2. 2.2 1์ฐจ ์—ฐ๊ตฌ
    3. 2.3 2์ฐจ ์—ฐ๊ตฌ
  3. 3 ์‹œ์žฅ ์—ญํ•™
    1. 3.1 ๋™์ธ
    2. 3.2 ์ œ์•ฝ
    3. 3.3 ๊ธฐํšŒ
    4. 3.4 ๊ณผ์ œ
    5. 3.5 ๊ฑฐ์‹œ๊ฒฝ์ œ ์ง€ํ‘œ
  4. 4 ์‹œ์žฅ ์š”์ธ ๋ถ„์„
    1. 4.1 ํฌํ„ฐ์˜ 5๊ฐ€์ง€ ํž˜ ๋ชจ๋ธ
      1. 4.1.1 ๊ณต๊ธ‰์—…์ฒด์˜ ํ˜‘์ƒ๋ ฅ
      2. 4.1.2 ๊ณ ๊ฐ์˜ ํ˜‘์ƒ๋ ฅ
      3. 4.1.3 ๊ฒฝ์Ÿ์—…์ฒด์˜ ๊ฐ•๋„
      4. 4.1.4 ์‹ ๊ทœ ์ง„์ž…์ž์˜ ์œ„ํ˜‘
  5. 5 ์„œ๋น„์Šค ์œ ํ˜•๋ณ„ ์ธ๋„ CRO ์‹œ์žฅ
    1. 5.1 ์„œ๋ก 
      1. 5.1.1 ์ž„์ƒ ์‹œํ—˜
      2. 5.1.2 ์ œํ’ˆ ๊ฐœ๋ฐœ
      3. 5.1.3 ๊ณต์ • ๊ฐœ๋ฐœ
      4. 5.1.4 ์‹œํŒ โ€‹โ€‹ํ›„ ๊ฐ์‹œ
      5. 5.1.5 ํ’ˆ์งˆ ๋ชจ๋‹ˆํ„ฐ๋ง
      6. 5.1.6 ๊ธฐํƒ€
  6. 6 ์น˜๋ฃŒ ์‘์šฉ ๋ถ„์•ผ๋ณ„ ์ธ๋„ CRO ์‹œ์žฅ
    1. 6.1 ์„œ๋ก 
      1. 6.1.1 ์ข…์–‘ํ•™
      2. 6.1.2 ์‹ฌํ˜ˆ๊ด€
      3. 6.1.3 ์‹ ๊ฒฝํ•™
      4. 6.1.4 ์‹ ์žฅํ•™ ๋ฐ ๋น„๋‡จ๊ธฐ๊ณผ
      5. 6.1.5 ์‹ฌํ˜ˆ๊ด€
      6. 6.1.6 ๊ธฐํƒ€
  7. 7 ์ตœ์ข… ์‚ฌ์šฉ์ž๋ณ„ ์ธ๋„ CRO ์‹œ์žฅ
    1. 7.1 ์„œ๋ก 
      1. 7.1.1 ์ œ์•ฝ/์ƒ๋ฌผ ์ œ์•ฝ ํšŒ์‚ฌ
      2. 7.1.3 ์˜๋ฃŒ ๊ธฐ๊ธฐ ํšŒ์‚ฌ
      3. 7.1.4 ํ•™์ˆ  ๊ธฐ๊ด€
  8. 8 ๊ตญ๊ฐ€๋ณ„ ์ธ๋„ CRO ์‹œ์žฅ
    1. 8.1 ์†Œ๊ฐœ
    2. 8.2 ๋ถ์ธ๋„
    3. 8.3 ๋‚จ์ธ๋„
    4. 8.4 ๋™์ธ๋„
    5. 8.5 ์„œ์ธ๋„
    6. 8.6 ์ค‘๋ถ€ ์ธ๋„
  9. 9 ํšŒ์‚ฌ ํ˜„ํ™ฉ
    1. 9.1 ์†Œ๊ฐœ
      1. 9.1.1 ํ•ฉ๋ณ‘ ์ธ์ˆ˜
      2. 9.1.2 ํ˜‘์—…
      3. 9.1.3 ์ถœ์‹œ/์‹ ์ œํ’ˆ ์ถœ์‹œ
      4. 9.1.4 ๊ธฐํƒ€(ํ™•์žฅ, ์—…๋ฐ์ดํŠธ, ํŒŒํŠธ๋„ˆ์‹ญ)
  10. 10 ํšŒ์‚ฌ ํ”„๋กœํ•„
    1. 10.1 Quintiles IMS Holdings, Inc.
      1. 10.1.1 ํšŒ์‚ฌ ๊ฐœ์š”
      2. 10.1.2 ์ œํ’ˆ/์‚ฌ์—… ๋ถ€๋ฌธ ๊ฐœ์š”
      3. 10.1.3 ์žฌ๋ฌด
      4. 10.1.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 10.1.5 SWOT ๋ถ„์„
    2. 10.2 Syngene, Pharmaceutical Product Development, LLC
      1. 10.2.1 ๊ฐœ์š”
      2. 10.2.2 ์ œํ’ˆ/์‚ฌ์—… ๋ถ€๋ฌธ ๊ฐœ์š”
      3. 10.2.3 ์žฌ๋ฌด
      4. 10.2.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 10.2.5 SWOT ๋ถ„์„
    3. 10.3 Siro Clinpharm
      1. 10.3.1 ๊ฐœ์š”
      2. 10.3.2 ์ œํ’ˆ/์‚ฌ์—… ๋ถ€๋ฌธ ๊ฐœ์š”
      3. 10.3.3 ์žฌ๋ฌด
      4. 10.3.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 10.3.5 SWOT ๋ถ„์„
    4. 10.4 VIMTA, Bilcare Limited
      1. 10.4.1 ๊ฐœ์š”
      2. 10.4.2 ์ œํ’ˆ/์‚ฌ์—… ๋ถ€๋ฌธ ๊ฐœ์š”
      3. 10.4.3 ์žฌ๋ฌด ์ •๋ณด
      4. 10.4.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 10.4.5 SWOT ๋ถ„์„
    5. 10.5 Aizant Drug Research Solutions Private Limited
      1. 10.5.1 ๊ฐœ์š”
      2. 10.5.2 ์ œํ’ˆ/์‚ฌ์—… ๋ถ€๋ฌธ ๊ฐœ์š”
      3. 10.5.3 ์žฌ๋ฌด ์ •๋ณด
      4. 10.5.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 10.5.5 SWOT ๋ถ„์„
    6. 10.6 Piramal Pharma Solutions
      1. 10.6.1 ๊ฐœ์š”
      2. 10.6.2 ์ œํ’ˆ/์‚ฌ์—… ๋ถ€๋ฌธ ๊ฐœ์š”
      3. 10.6.3 ์žฌ๋ฌด ์ •๋ณด
      4. 10.6.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 10.6.5 SWOT ๋ถ„์„
    7. 10.7 Synapse Labs Pvt ์ œํ•œ์ 
      1. 10.7.1 ๊ฐœ์š”
      2. 10.7.2 ์ œํ’ˆ/์‚ฌ์—… ๋ถ€๋ฌธ ๊ฐœ์š”
      3. 10.7.3 ์žฌ๋ฌด ์ •๋ณด
      4. 10.7.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 10.7.5 SWOT ๋ถ„์„
    8. 10.8 Eurofins Scientific
      1. 10.8.1 ๊ฐœ์š”
      2. 10.8.2 ์ œํ’ˆ/์‚ฌ์—… ๋ถ€๋ฌธ ๊ฐœ์š”
      3. 10.8.3 ์žฌ๋ฌด ์ •๋ณด
      4. 10.8.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 10.8.5 SWOT ๋ถ„์„
    9. 10.9 Laurus Labs., Neuland Laboratories Ltd
      1. 10.9.1 ๊ฐœ์š”
      2. 10.9.2 ์ œํ’ˆ/์‚ฌ์—… ๋ถ€๋ฌธ ๊ฐœ์š”
      3. 10.9.3 ์žฌ๋ฌด ์ •๋ณด
      4. 10.9.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 10.9.5 SWOT ๋ถ„์„
    10. 10.10 PAREXEL International Corporation
      1. 10.10.1 ๊ฐœ์š”
      2. 10.10.2 ์ œํ’ˆ/์‚ฌ์—… ๋ถ€๋ฌธ ๊ฐœ์š”
      3. 10.10.3 ์žฌ๋ฌด ์ •๋ณด
      4. 10.10.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 10.10.5 SWOT ๋ถ„์„
    11. 10.11 ๊ธฐํƒ€
  11. 11 ๋ถ€๋ก
    1. ํ‘œ ๋ชฉ๋ก
    2. ํ‘œ 1 ์ธ๋„ CRO ์‹œ์žฅ, 2020-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ)
    3. ํ‘œ 2 ์„œ๋น„์Šค ์œ ํ˜•๋ณ„ ์ธ๋„ CRO ์‹œ์žฅ, 2020-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ)
    4. ํ‘œ 3 ์น˜๋ฃŒ์  ์ ์šฉ๋ณ„ ์ธ๋„ CRO ์‹œ์žฅ, 2020-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ) 10์–ต ๋‹ฌ๋Ÿฌ)
    5. ํ‘œ 4 ์ตœ์ข… ์‚ฌ์šฉ์ž๋ณ„ ์ธ๋„ CRO ์‹œ์žฅ, 2020-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ)
    6. ํ‘œ 5 ์ง€์—ญ๋ณ„ ์ธ๋„ CRO ์‹œ์žฅ, 2020-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ)
    7. ๊ทธ๋ฆผ ๋ชฉ๋ก
    8. ๊ทธ๋ฆผ 1 ์—ฐ๊ตฌ ํ”„๋กœ์„ธ์Šค
    9. ๊ทธ๋ฆผ 2 ํฌํ„ฐ์˜ 5๊ฐ€์ง€ ํž˜ ๋ชจ๋ธ
    10. ๊ทธ๋ฆผ 3 ์„œ๋น„์Šค ์œ ํ˜•๋ณ„ ์ธ๋„ CRO ์‹œ์žฅ
    11. ๊ทธ๋ฆผ 4 ์น˜๋ฃŒ ์‘์šฉ ๋ถ„์•ผ๋ณ„ ์ธ๋„ CRO ์‹œ์žฅ
    12. ๊ทธ๋ฆผ 5 ์ตœ์ข… ์‚ฌ์šฉ์ž๋ณ„ ์ธ๋„ CRO ์‹œ์žฅ
    13. ๊ทธ๋ฆผ 6 ์ง€์—ญ๋ณ„ ์ธ๋„ CRO ์‹œ์žฅ ์ง€์—ญ
    14. ๊ทธ๋ฆผ 7 ์ธ๋„ CRO ์‹œ์žฅ: ํšŒ์‚ฌ ์ ์œ ์œจ ๋ถ„์„, 2023(%)

์‹œ์žฅ ์„ธ๋ถ„ํ™”

์ธ๋„ CRO ์‹œ์žฅ ์„œ๋น„์Šค ์œ ํ˜• ์ „๋ง(10์–ต ๋‹ฌ๋Ÿฌ, 2018-2032๋…„)

  • ์ž„์ƒ ์‹œํ—˜

  • ์ œํ’ˆ ๊ฐœ๋ฐœ

  • ๊ณต์ • ๊ฐœ๋ฐœ

  • ์‹œํŒ ํ›„ ๊ฐ์‹œ

  • ํ’ˆ์งˆ ๋ชจ๋‹ˆํ„ฐ๋ง ๊ธฐํƒ€

์ธ๋„ CRO ์‹œ์žฅ ์‘์šฉ ์ „๋ง(10์–ต ๋‹ฌ๋Ÿฌ, 2018-2032)

  • ์ข…์–‘ํ•™

  • ์‹ฌํ˜ˆ๊ด€ํ•™

  • ์‹ ๊ฒฝํ•™

  • ์‹ ์žฅํ•™

  • ๋น„๋‡จ๊ธฐ๊ณผ

  • ๊ธฐํƒ€

์ธ๋„ CRO ์‹œ์žฅ ์ตœ์ข… ์‚ฌ์šฉ์ž ์ „๋ง(10์–ต ๋‹ฌ๋Ÿฌ, 2018-2032)

  • ์ œ์•ฝ/๋ฐ”์ด์˜ค ์ œ์•ฝ ํšŒ์‚ฌ

  • ์˜๋ฃŒ๊ธฐ๊ธฐ ํšŒ์‚ฌ

  • ํ•™์ˆ  ๊ธฐ๊ด€

Case Study Cover Image
์‚ฌ๋ก€ ์—ฐ๊ตฌ

Aerospace & Defense